文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

抗PD-1与抗PD-L1药物免疫相关不良事件的系统综述与Meta分析

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2018-03-14

该系统综述与Meta分析评估了抗PD-1药物(纳武利尤单抗、帕博利珠单抗、阿替利珠单抗)相比对照治疗在癌症患者中器官特异性免疫相关严重不良事件、免疫激活相关一般不良事件及肌肉骨骼问题的发生率。共纳入13项研究,发现严重器官特异性免疫相关不良事件罕见,但甲状腺功能减退、肺炎、结肠炎和垂体炎风险显著增加;疲劳和腹泻发生率高但与对照相似;肌肉骨骼问题报告不一致但可能常见。

要点

  • 抗PD-1药物相比对照治疗显著增加甲状腺功能减退、肺炎、结肠炎和垂体炎风险。
  • 免疫激活相关一般不良事件中仅皮疹风险增加,疲劳和腹泻发生率高但与对照相似。
  • 肌肉骨骼问题报告不一致,但某些研究中关节痛和背痛发生率超过20%。

核心结论

  • 抗PD-1药物器官特异性免疫相关不良事件不常见,但风险相比对照治疗增加。
  • 免疫激活相关一般不良事件与对照 largely 相似。
  • 肌肉骨骼问题报告不一致,但不良事件可能常见。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase、Cochrane Library、Web of Science和Scopus至2017年3月16日,并结合ClinicalTrials.gov数据。
  • 纳入13项研究,比较纳武利尤单抗(n=6)、帕博利珠单抗(5)或阿替利珠单抗(2)与化疗(11)、靶向药物(1)或两者(1)。
  • 8项研究有ClinicalTrials.gov的不良事件数据,三名独立研究者提取数据并评估偏倚风险。

主要发现

  • 相比标准治疗,抗PD-1药物增加甲状腺功能减退(OR 7.56, 95%CI 4.53-12.61)、肺炎(5.37, 2.73-10.56)、结肠炎(2.88, 1.30-6.37)和垂体炎(3.38, 1.02-11.08)风险。
  • 免疫激活相关一般不良事件中仅皮疹风险增加(2.34, 2.73-10.56)。
  • 疲劳发生率32%、腹泻19%,与对照相似。
  • 肌肉骨骼问题报告不一致,某些研究中关节痛和背痛发生率超过20%。

临床怎么用

  • 临床使用抗PD-1药物时应监测甲状腺功能减退、肺炎、结肠炎和垂体炎等免疫相关不良事件。
  • 对疲劳和腹泻等高发但非特异症状,需与对照治疗类似管理。
  • 肌肉骨骼症状可能常见,应关注关节痛和背痛的报告与评估。

局限性

  • 仅8项研究有ClinicalTrials.gov的不良事件数据,可能影响完整性。
  • 肌肉骨骼问题报告不一致,发生率变异大。
  • 研究截至2017年3月,可能未涵盖后续新数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events consistent with musculoskeletal problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control treatments. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, Cochrane Library, Web of Science, and Scopus searched to 16 March 2017 and combined with data from ClinicalTrials.gov. STUDY SELECTION: Eligible studies included primary clinical trial data on patients with cancer with recurrent or metastatic disease. DATA EXTRACTION: Three independent investigators extracted data on adverse events from ClinicalTrials.gov and the published studies. Risk of bias was assessed using the Cochrane tool by three independent investigators. RESULTS: 13 relevant studies were included; adverse event data were available on ClinicalTrials.gov for eight. Studies compared nivolumab (n=6), pembrolizumab (5), or atezolizumab (2) with chemotherapy (11), targeted drugs (1), or both (1). Serious organ specific immune-related adverse events were rare, but compared with standard treatment, rates of hypothyroidism (odds ratio 7.56, 95% confidence interval 4.53 to 12.61), pneumonitis (5.37, 2.73 to 10.56), colitis (2.88, 1.30 to 6.37), and hypophysitis (3.38, 1.02 to 11.08) were increased with anti-PD-1 drugs. Of the general adverse events related to immune activation, only the rate of rash (2.34, 2.73 to 10.56) increased. Incidence of fatigue (32%) and diarrhea (19%) were high but similar to control. Reporting of adverse events consistent with musculoskeletal problems was inconsistent; rates varied but were over 20% in some studies for arthraligia and back pain. CONCLUSIONS: Organ specific immune-related adverse events are uncommon with anti-PD-1 drugs but the risk is increased compared with control treatments. General adverse events related to immune activation are largely similar. Adverse events consistent with musculoskeletal problems are inconsistently reported but adverse events may be common.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018. PMID: 29540345. doi:10.1136/bmj.k793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。